SecBot SecBot
8-K ·Filed Apr 29, 2026
TL

TLSIW

TriSalus Life Sciences, Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed6mo ago SEC0001628280-26-028425
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

No immediate trading action warranted. Monitor for any successor announcement for the Chief of Clinical Operations role, which could signal organizational stability or disruption.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
TLSIW ▼ -11.11% at T+60d
NEUTRAL call -11.11% · α vs SPY -14.22% · entry $0.9900 → $0.8800
Entry = T+0 close
Apr 29, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.22%
$0.9900
settled 6mo ago
T+5d
+1.01%
call +1.01% · α -0.72%
$1.00
settled 6mo ago
T+20d
-32.53%
call -32.53% · α -37.75%
$0.6680
settled 5mo ago
T+60d
-11.11%
call -11.11% · α -14.22%
$0.8800
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

TriSalus Life Sciences disclosed the planned retirement of Chief of Clinical Operations Jodi Devlin, effective October 1, 2026, and reiterated the previously announced appointment of Dr. Richard Marshall as Chief Medical Officer effective June 29, 2026. This is a routine officer transition with no financial impact or red flags.

Key Facts

  • Chief of Clinical Operations Jodi Devlin notified the company of her retirement on April 24, 2026, effective October 1, 2026.
  • Dr. Richard Marshall was previously appointed as Chief Medical Officer, effective June 29, 2026, as announced on April 7, 2026.
  • No replacement for Devlin has been named in this filing.

Financial Impact

No financial figures disclosed; routine officer retirement with no compensation details or severance mentioned.

Risk Factors

  • Key personnel transition in clinical operations could cause temporary operational disruption if a replacement is not named promptly.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-028425
Document: 0001628280-26-028425-index-headers.html0001628280-26-028425
Document: 0001628280-26-028425-index.html0001628280-26-028425
Document: 0001628280-26-028425.txt0001628280-26-028425
2 reports for TLSIW
Performance horizon
Filters
Rows
Reports for TLSIW — sortable, filterable
TypeNow
Apr 29, 2026
25w ago
8-K
NEUTRAL ★ 2/10
$0.9900 $0.6680▼ −32.53%▼ −37.75%$0.7500 (−24.24%)
Apr 7, 2026
28w ago
8-K
NEUTRAL ★ 3/10
$1.19 $1.00▼ −15.97%▼ −25.75%$0.7500 (−36.97%)
Showing 2 of 2

US Market Status

Market Closed — Opens in 9h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 29, 2026